Ovid Therapeutics (OVID) Revenue & Revenue Breakdown
Ovid Therapeutics Revenue Highlights
Latest Revenue (Y)
$566.00K
Latest Revenue (Q)
$130.00K
Main Segment (Y)
License
Ovid Therapeutics Revenue by Period
Ovid Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | $566.00K | 44.50% |
| 2023-12-31 | $391.69K | -73.93% |
| 2022-12-31 | $1.50M | -99.28% |
| 2021-12-31 | $208.38M | 1551.57% |
| 2020-12-31 | $12.62M | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2015-12-31 | - | 100.00% |
| 2014-12-31 | - | - |
Ovid Therapeutics generated $566.00K in revenue during NA 2024, up 44.50% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Ovid Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-03-31 | $130.00K | 71.05% |
| 2024-12-31 | $76.00K | -56.07% |
| 2024-09-30 | $173.00K | 2.37% |
| 2024-06-30 | $169.00K | 14.19% |
| 2024-03-31 | $148.00K | 4.55% |
| 2023-12-31 | $141.56K | 29.91% |
| 2023-09-30 | $108.97K | 45.30% |
| 2023-06-30 | $75.00K | 13.64% |
| 2023-03-31 | $66.00K | 42.61% |
| 2022-12-31 | $46.28K | 316.86% |
| 2022-09-30 | $11.10K | 100.00% |
| 2022-06-30 | - | -100.00% |
| 2022-03-31 | $1.45M | -100.35% |
| 2021-12-31 | $-416.35M | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | -100.00% |
| 2021-03-31 | $208.38M | 3553.92% |
| 2020-12-31 | $5.70M | -17.52% |
| 2020-09-30 | $6.91M | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2017-09-30 | - | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2016-09-30 | - | 100.00% |
| 2016-06-30 | - | 100.00% |
| 2016-03-31 | - | - |
Ovid Therapeutics generated $130.00K in revenue during Q1 2025, up 71.05% compared to the previous quarter, and up 91.83% compared to the same period a year ago.
Ovid Therapeutics Revenue Breakdown
Ovid Therapeutics Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 22 | Dec 21 |
|---|---|---|
| Related Party | - | $196.00M |
| License | $1.50M | $12.38M |
Latest
Ovid Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 22: License (100.00%).
Quarterly Revenue by Product
| Product/Service | Jun 25 | Mar 25 | Dec 22 | Sep 22 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|---|
| Reportable Segment | $6.27M | $130.00K | - | - | - | - |
| License | - | - | $46.28K | $11.10K | $1.45M | $12.38M |
| Related Party | - | - | - | - | - | $196.00M |
Latest
Ovid Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Jun 25: Reportable Segment (100.00%).
Ovid Therapeutics Revenue Breakdown by Country
Quarterly Revenue by Country
| Country | Sep 22 | Mar 22 | Mar 21 |
|---|---|---|---|
| License | $11.10K | $1.45M | $12.38M |
| Related Party | - | - | $196.00M |
Latest
Ovid Therapeutics's latest quarterly revenue breakdown by geography, as of Sep 22: License (100.00%).
Ovid Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| COYA | Coya Therapeutics | $3.55B | $163.62K |
| MGNX | MacroGenics | $149.96M | $13.19M |
| SEER | Seer | $14.17M | $4.21M |
| IRD | Opus Genetics | $10.99M | $4.37M |
| TCRX | TScan Therapeutics | $2.82M | - |
| VTGN | VistaGen Therapeutics | $1.06M | $-15.00K |
| OVID | Ovid Therapeutics | $566.00K | $130.00K |
| CNTX | Context Therapeutics | - | - |
| HURA | TuHURA Biosciences | - | - |
| ONCY | Oncolytics Biotech | - | - |